Barclays
WST icon

Barclays’s West Pharmaceutical WST Stock Holding History

Barclays’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.5M Buy
349,104
+206,919
+146% +$51.5M 0.02% 537
2025
Q4 		$39.1M Buy
142,185
+2,169
+2% +$593K 0.01% 899
2025
Q3 		$36.7M Sell
140,016
-59,572
-30% -$14.5M 0.01% 912
2025
Q2 		$43.7M Buy
199,588
+7,412
+4% +$1.58M 0.01% 763
2025
Q1 		$43M Buy
192,176
+51,044
+36% +$14.1M 0.01% 704
2024
Q4 		$46.2M Sell
141,132
-114,053
-45% -$35.9M 0.01% 698
2024
Q3 		$76.6M Buy
255,185
+83,710
+49% +$25.6M 0.02% 529
2024
Q2 		$56.5M Buy
171,475
+20,815
+14% +$7.36M 0.02% 578
2024
Q1 		$59.6M Sell
150,660
-25,556
-15% -$9.45M 0.02% 551
2023
Q4 		$62M Buy
176,216
+18,220
+12% +$6.45M 0.02% 572
2023
Q3 		$59.3M Buy
157,996
+27,264
+21% +$10.5M 0.04% 435
2023
Q2 		$50M Buy
130,732
+60,041
+85% +$21.4M 0.03% 446
2023
Q1 		$24.5M Sell
70,691
-24,767
-26% -$7.24M 0.01% 770
2022
Q4 		$22.5M Buy
95,458
+16,704
+21% +$3.96M 0.01% 835
2022
Q3 		$19.4M Buy
78,754
+689
+0.9% +$210K 0.02% 616
2022
Q2 		$23.6M Sell
78,065
-70,684
-48% -$23M 0.01% 649
2022
Q1 		$61.1M Buy
148,749
+7,575
+5% +$2.97M 0.05% 363
2021
Q4 		$66.2M Buy
141,174
+25,701
+22% +$11.1M 0.02% 474
2021
Q3 		$49M Sell
115,473
-654
-0.6% -$276K 0.02% 530
2021
Q2 		$41.7M Buy
116,127
+19,099
+20% +$6.31M 0.02% 586
2021
Q1 		$27.3M Buy
97,028
+29,082
+43% +$8.32M 0.01% 684
2020
Q4 		$19.2M Buy
67,946
+6,707
+11% +$1.88M 0.01% 854
2020
Q3 		$16.8M Buy
61,239
+7,762
+15% +$2.05M 0.01% 819
2020
Q2 		$12.2M Buy
53,477
+13,497
+34% +$2.65M 0.01% 863
2020
Q1 		$6.09M Sell
39,980
-42,691
-52% -$6.57M ﹤0.01% 1313
2019
Q4 		$12.4M Sell
82,671
-17,681
-18% -$2.57M 0.01% 1238
2019
Q3 		$14.2M Buy
100,352
+72,629
+262% +$10M 0.01% 1080
2019
Q2 		$3.47M Sell
27,723
-11,026
-28% -$1.3M ﹤0.01% 2259
2019
Q1 		$4.27M Buy
38,749
+19,498
+101% +$2.03M ﹤0.01% 1781
2018
Q4 		$1.89M Sell
19,251
-6,592
-26% -$715K ﹤0.01% 2467
2018
Q3 		$3.19M Buy
25,843
+20,284
+365% +$2.27M ﹤0.01% 2327
2018
Q2 		$553K Sell
5,559
-24,957
-82% -$2.3M ﹤0.01% 3854
2018
Q1 		$2.69M Buy
30,516
+27,709
+987% +$2.59M ﹤0.01% 2178
2017
Q4 		$277K Buy
2,807
+1,861
+197% +$182K ﹤0.01% 4409
2017
Q3 		$92K Sell
946
-10,252
-92% -$928K ﹤0.01% 4984
2017
Q2 		$1.06M Buy
11,198
+1,057
+10% +$97.2K ﹤0.01% 2837
2017
Q1 		$827K Buy
10,141
+2,814
+38% +$235K ﹤0.01% 2902
2016
Q4 		$621K Buy
7,327
+4,113
+128% +$323K ﹤0.01% 3173
2016
Q3 		$239K Sell
3,214
-18,438
-85% -$1.46M ﹤0.01% 3815
2016
Q2 		$1.64M Buy
21,652
+20,874
+2,683% +$1.52M ﹤0.01% 2179
2016
Q1 		$53K Sell
778
-2,838
-78% -$171K ﹤0.01% 4730
2015
Q4 		$217K Buy
3,616
+2,387
+194% +$144K ﹤0.01% 3845
2015
Q3 		$66K Sell
1,229
-193
-14% -$11.2K ﹤0.01% 4862
2015
Q2 		$83K Sell
1,422
-739
-34% -$41.2K ﹤0.01% 4798
2015
Q1 		$129K Sell
2,161
-3,725
-63% -$199K ﹤0.01% 4675
2014
Q4 		$312K Sell
5,886
-3,260
-36% -$163K ﹤0.01% 4271
2014
Q3 		$402K Buy
9,146
+7,877
+621% +$335K ﹤0.01% 4147
2014
Q2 		$54K Sell
1,269
-1,597
-56% -$68.4K ﹤0.01% 5880
2014
Q1 		$125K Sell
2,866
-63,008
-96% -$2.97M ﹤0.01% 5254
2013
Q4 		$3.23M Buy
65,874
+18,016
+38% +$843K ﹤0.01% 2194
2013
Q3 		$1.96M Sell
47,858
-23,040
-32% -$879K ﹤0.01% 2599
2013
Q2 		$2.49M Buy
+70,898
New +$2.33M ﹤0.01% 2300

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's WST Position: Q1 2026 in Review

Barclays increased its West Pharmaceutical (WST) stake by 146% in Q1 2026, buying an estimated $51.5M and bringing the position to 349,104 shares worth $87.5M. The position accounts for 0.02% of the portfolio, ranked #537.

Barclays first reported a position in WST in Q2 2013 and has held it in 52 quarters since. 754 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Barclays held 349,104 shares of West Pharmaceutical worth $87.5M as of Q1 2026.
  • Barclays bought 206,919 West Pharmaceutical shares in Q1 2026, an estimated $51.5M.
  • West Pharmaceutical made up 0.02% of Barclays's portfolio in Q1 2026, its #537 holding.
  • Barclays first reported a position in West Pharmaceutical in Q2 2013 and has held it in 52 quarters since.
  • 754 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.